{
  "metadata": {
    "name": "MRS. RIDHIMA TAYAL",
    "cr_no": "319423",
    "age_sex": "33Y/Female",
    "referred_doctor": "Dr. Dinesh Bhurani/Rohan",
    "sample_type": "Bone Marrow Aspirate",
    "diagnosis": "Acute Myeloid Leukemia",
    "tumor_fraction": "",
    "order_no": "",
    "order_date": "11.08.2026",
    "receiving_date": "11.08.2026",
    "reporting_date": "24.08.2026",
    "lab_id": "2026223-2089"
  },
  "report_information": {
    "panel_title": "Next Generation Sequencing based Myeloid Panel"
  },
  "clinical_content": {
    "sections": [
      {
        "heading": "_preamble",
        "order": 1,
        "content": "BLAST: 06 (BMA Myelogram)",
        "page": 1,
        "source_lines": [
          58
        ]
      },
      {
        "heading": "Report Highlights",
        "order": 2,
        "content": "No clinically significant alteration(s) is detected in the genes analyzed.",
        "page": 1,
        "source_lines": [
          60
        ],
        "children": [
          {
            "heading": "Genomic Assembly",
            "order": 3,
            "content": "GrCH 37(hg19)",
            "page": 1,
            "source_lines": [
              61
            ]
          },
          {
            "heading": "Additional Note",
            "order": 4,
            "content": "FLT3 D835 variant was not detected in the current MRD specimen.",
            "page": 1,
            "source_lines": [
              63
            ]
          },
          {
            "heading": "Assay Information and Methodology",
            "order": 5,
            "content": "The assay utilizing a minimum of 10ng of DNA and 10ng of RNA at 500X coverage provides an analytical sensitivity of more than equal to 5\npercent for DNA-based genetic alteration.\nVariants of strong and potential clinical significance are only reported in somatic panels.",
            "page": 1,
            "source_lines": [
              64,
              98,
              99,
              102
            ],
            "children": [
              {
                "heading": "Test Description",
                "order": 6,
                "content": "Oncomine Myeloid Assay is a comprehensive, targeted NGS assay which interrogates the below mentioned genes for all relevant\nDNA alterations and gene rearrangements associated with myeloid malignancies viz-a-vis acute myeloid leukemia (AML), myelodysplastic syndromes\n(MDS), myeloproliferative neoplasms (MPN), MDS/MPN, in a single run",
                "page": 1,
                "source_lines": [
                  67,
                  68,
                  69
                ]
              },
              {
                "heading": "Gene Analyzed for SNVs",
                "order": 7,
                "content": "ABL1, ASXL1, BAALC, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, EIF2B1, FLT3, FBXW2,GATA2, HRAS,\nIDH1, IDH2, IKZF1,JAK2, KIT, KRAS, MECOM, MPL, MYC, MYD88, NF1, NPM1, NRAS, PHF6, PRPF8, PSMB2, PTPN11,PUM1, RB1, RUNX1, SETBP1,\nSF3B1, SH2B3, SMC1A, SRSF2, STAG2, TET2, TRIM27, TP53, U2AF1, WT1, ZRSR2.",
                "page": 1,
                "source_lines": [
                  72,
                  73,
                  74
                ]
              },
              {
                "heading": "Genes Analyzed for Rearrangements",
                "order": 8,
                "content": "ABL1, ALK, BCL2, BRAF, CCND1, CREBBP, EGFR, ETV6, FGFR1, FGFR2, FUS, HMGA2, JAK2, KMT2A (MLL),\nMECOM, MET, MLLT10, MLLT3, MYBL1, MYH11, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1",
                "page": 1,
                "source_lines": [
                  77,
                  78
                ]
              },
              {
                "heading": "Quality Metrics",
                "order": 9,
                "metrics": {
                  "DNA": {
                    "status": "PASSED",
                    "Mean depth of coverage": "6514x",
                    "Uniformity": "98.90%"
                  },
                  "RNA": {
                    "status": "PASSED",
                    "Total mapped fusion reads": "537,130 (Cutoff>200000)"
                  }
                },
                "page": 1,
                "source_lines": [
                  81,
                  84,
                  87,
                  89,
                  92,
                  95
                ]
              },
              {
                "heading": "Disclaimer",
                "order": 10,
                "content": "The information in this report does not constitute a treatment recommendation or recommendation to not using any specific therapeutic agent,\nand it should not be interpreted as treatment advice. Decisions concerning patient care and treatment rest solely within the discretion of the patient's\ntreating physician.",
                "page": 1,
                "source_lines": [
                  105,
                  106,
                  107
                ]
              }
            ]
          }
        ]
      }
    ]
  },
  "authorization": {
    "performed_by": "Mamta Arya Scientist C\nAmit Negi Scientist A\nAkaash Kumar Scientist B\nMolecular Diagnostics",
    "reviewed_by": "Dr Rushali Saxena\nAttending consultant, Pathology",
    "approved_by": "Dr. Anurag Mehta\nPrincipal Director Laboratory Services\nRajiv Gandhi Cancer Institute & Research Centre.\nRohini, New Delhi."
  },
  "processing": {
    "source_file": "/app/uploads/29383_COMPREHENSIVE MYELOID PANEL NGS(AML,MDS,MPN,CML,CMML & JMML).pdf",
    "content_hash": "f01292d2d688e2b68aa59890a43ccc0af0f8365737770952ba9ff77ab88cdf92",
    "processed_at": "2026-09-12T10:18:23.838647+00:00",
    "pipeline_version": "1.0.0",
    "pipeline_name": "molecular",
    "pages": 1,
    "sections_detected": 2,
    "warnings_count": 1,
    "skipped_image_blocks": 1,
    "skipped_figure_lines": 0,
    "content_coverage": 0.9688,
    "validation_status": "PASSED",
    "validation_failures": [],
    "validation_warnings": [],
    "header_layout": "B"
  }
}